Working… Menu

Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02236572
Recruitment Status : Completed
First Posted : September 10, 2014
Last Update Posted : January 28, 2021
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Yale University

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : November 23, 2020
Actual Study Completion Date : November 23, 2020